[Clozapine-resistant schizophrenia related to an increased metabolism and benefit of fluvoxamine: four case reports].

Objective: Although clozapine currently remains the most effective option in treatment-resistant schizophrenia, approximately 40-70% of antipsychotic-resistant patients do not respond, or respond only partially, to clozapine. Because clozapine-resistant patients have limited alternative treatment options, in this study we propose a clozapine augmentation strategy with evidence-based support for some of them.

Background: Clozapine-resistance is often of metabolic origin.